Bio

Dr. Koo is a board-certified ophthalmologist with the Byers Eye Institute at Stanford Health Care and a clinical assistant professor in the Department of Ophthalmology.

Dr. Koo diagnoses and treats a wide range of eye conditions, such as blepharitis, macular degeneration, diabetic retinopathy, farsightedness, cataracts, and glaucoma. She performs a range of surgical procedures, including cataract surgery, chalazia excisions, and laser glaucoma surgery. Dr. Koo creates a comprehensive, personalized treatment plan for each of her patients.

In addition to her clinical responsibilities, Dr. Koo is involved in the education and oversight of medical students, interns, and Ophthalmology residents spanning all settings from the classroom to the clinic, operating room, and the hospital.

Dr. Koo researches best practices in ophthalmologic care. Her research has included case studies to evaluate treatments in adults and children.

Dr. Koo’s work has been published in peer-reviewed journals, including Retina and the Journal of Pediatric Ophthalmology and Strabismus. She has been invited to moderate and present at regional, national, and international meetings, including the World Ophthalmology Congress.

Clinical Focus

  • Ophthalmology

Academic Appointments

  • Clinical Assistant Professor, Ophthalmology

Professional Education

  • Board Certification: American Board of Ophthalmology, Ophthalmology (2020)
  • Residency: Bascom Palmer Eye Institute (2019) FL
  • Internship: Beth Israel Deaconess Medical Center Internal Medicine Residency (2016) MA
  • Medical Education: Harvard Medical School (2015) MA
  • Bachelor of Science, University of Florida, Biochemistry, Business Admin (2009)

Contact

  • Academic
    University - Academic staff Department: Ophthalmology Clinic and Education Position: Clinical Assistant Professor
  • Clinical (Primary)  Stanford Byers Eye Institute 2452 Watson Ct MC 5353 Palo Alto, CA 94303 (650) 725-6619 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5353

2024-25 Courses

All Publications

  • High Myopia and Capsular Tension Rings-To Be or Not To Be? JAMA OPHTHALMOLOGY Koo, E. B. 2025

    View details for DOI 10.1001/jamaophthalmol.2025.0442

    View details for Web of Science ID 001449664900001

    View details for PubMedID 40111350

  • Risk of Cataract Surgery Complications in Patients with Prior Intravitreal Injection Therapy. American journal of ophthalmology Zhao, C. S., Chwialkowski, K., Wai, K. M., Mruthyunjaya, P., Rahimy, E., Koo, E. B. 2025

    Abstract

    To compare the rate of cataract surgery complications in patients with and without prior intravitreal injection (IVI) pharmacotherapy.A retrospective cohort study was performed using the TriNetX (Cambridge, MA) aggregated electronic health records research network.Patients with a history of IVI therapy within twenty years of cataract surgery were compared to a control group using propensity score matching (PSM) to balance for baseline demographics, systemic, and ocular co-morbidities. Patients with a history of lensectomy or pars plana vitrectomy (PPV) prior to cataract surgery were excluded.IVI therapy within twenty years of cataract surgery.Rate of retinal detachment (RD), RD repair, anterior vitrectomy, retained lens, dislocated intraocular lens (IOL), need for a secondary lens procedure, and endophthalmitis within 14, 30, and 90 days of cataract surgery.Prior to PSM, 16,356 and 512,152 patients did and did not, respectively, have IVI pharmacotherapy prior to cataract surgery. After PSM, both groups had 14,240 patients. A higher rate (RR 1.34; 95% CI, 1.16-1.54; p<0.0005) of aggregate complications within 90 days of cataract surgery was found in the group with prior IVI (447/13,719 = 3.3%) relative to controls (340/13,945=2.4%). The exposure group saw an increased risk of RD repair at 30 days (RR 1.84; 95% CI, 1.27-2.66; p=0.001) and 90 days (RR 2.05; 95% CI, 1.65-2.54; p<0.0005). No other complications were associated with IVI. In particular, IVI was not associated with higher rates of anterior vitrectomy except in patients with diabetic retinopathy (DR) at 90 days (RR 1.24; 95% CI, 0.85-1.79; p=0.001). Patients with DR and prior IVI had a higher risk of lensectomy, RD repair, and secondary procedures (p < 0.0005 for all) compared to DR patients without prior IVI.Patients with prior IVI saw more complications following cataract surgery, primarily for RD. IVI treatment history should be considered in pre-operative planning.

    View details for DOI 10.1016/j.ajo.2025.01.004

    View details for PubMedID 39826858

  • Reply to Comment on Ophthalmic Immune-Related Adverse Events and Association with Survival: Results from a Real-World Database. American journal of ophthalmology Quiruz, L., Yavari, N., Kikani, B., Gupta, A. S., Wai, K. M., Kossler, A. L., Ludwig, C., Koo, E. B., Rahimy, E., Mruthyunjaya, P. 2024

    View details for DOI 10.1016/j.ajo.2024.11.001

    View details for PubMedID 39528009

  • Endogenous Fusarium Endophthalmitis after Bone Marrow Transplant: A Case Report and Literature Review. Vision (Basel, Switzerland) Zhao, C. S., Wai, K., Koo, E. B., Rahimy, E., Mruthyunjaya, P., Mahajan, V. B., DeBoer, C. M. 2024; 8 (3)

    Abstract

    We aim to present a case of disseminated fusariosis that occurred in the setting of immunosuppression and presented with bilateral endogenous endophthalmitis, along with a literature review of Fusarium endophthalmitis, highlighting management strategies.A 70-year-old male with acute myeloid leukemia who had recently undergone a bone marrow transplant noted bilateral floaters and decreased vision. He was found to have bilateral Fusarium endophthalmitis, with subsequent evidence of fungemia and fusariosis in his skin and joints. Despite aggressive local and systemic treatment, he succumbed to the disease. Endophthalmitis was initially stabilized with pars plana vitrectomy and intravitreal amphotericin and voriconazole until the patient transitioned to comfort measures. A review of 31 cases demonstrates that outcomes are poor and that the disease must be treated aggressively, often both systemically and surgically.This case highlights the recalcitrance of Fusarium bacteremia and Fusarium endophthalmitis.

    View details for DOI 10.3390/vision8030044

    View details for PubMedID 39051230